Praluent reduces need for apheresis in HeFH patients

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Sanofi (Euronext:SAN; NYSE:SNY) said Praluent alirocumab met the primary endpoint of reducing the frequency of apheresis among heterozygous familial hypercholesterolemia patients in the Phase III ODYSSEY ESCAPE trial. The companies said patients who received the PCSK9 inhibitor on top of an existing regimen had a 75% reduction in apheresis frequency vs. placebo (p<0.0001).

The partners said 63% of patients who received Praluent no longer required apheresis, compared to zero patients receiving placebo. ...